◎ Sugi Atlas

Atlas / Drug / Ibuprofen

Ibuprofen

drug
On this page

Also known as Aches-n-painAdvilAdvil liqui-gelsAdvil migraine liqui-gelsAnadin joint painAnadin liquifastAnadin period pain reliefAnadin ultraApsifenApsifen-fArthrofen 200Arthrofen 400Arthrofen 600Brufen retBuranaCaldolorCap-profenChildren's advilChildren's advil-flavoredChildren's elixsure

Summary

Ibuprofen (CHEMBL521) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC G02CC01) targeting SLC36A1, PTGS1, and PTGS2; indicated across 86 conditions including vaginitis and common cold; with CIViC clinical evidence for 1 variant-indication association (e.g. PIK3CA Amplification in head and neck squamous cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: G02CC01 (+5 more)
  • Targets: 6 (SLC36A1, PTGS1, PTGS2…)
  • Indications: 86 conditions
  • Clinical trials: 578
  • Precision-oncology evidence (CIViC): 1 variant–indication association
  • Chemistry: 206.28 Da · C13H18O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL521
NameIbuprofen
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID3672
ChEBICHEBI:5855
ATCG02CC01, M01AE51, M02AA13, R02AX02, C01EB16, M01AE01
Molecular formulaC13H18O2
Molecular weight206.28
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N

SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(=O)O

IUPAC name: 2-[4-(2-methylpropyl)phenyl]propanoic acid

ChEBI definition: A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, cyclooxygenase 2 inhibitor, cyclooxygenase 1 inhibitor, antipyretic, radical scavenger, drug allergen, geroprotector.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Aches-n-pain, Advil, Advil liqui-gels, Advil migraine liqui-gels, Anadin joint pain, Anadin liquifast, Anadin period pain relief, Anadin ultra, Apsifen, Apsifen-f, Arthrofen 200, Arthrofen 400

Parent form; salt/anhydrous children: CHEMBL1201141, CHEMBL1241153, CHEMBL3989408, CHEMBL4594450, CHEMBL5201530

Patent coverage: 70,968 distinct patent families (228,490 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SLC36A1Proton-coupled Amino acid Transporter 1Inhibition3.020.2%Q7Z2H8
PTGS1COX-1Inhibition5.520%P23219
PTGS2COX-2Inhibition5.870%P35354
PPARGPeroxisome proliferator-activated receptor-γFull agonist2.6%P37231
ASIC1ASIC13.52.6%P78348
SLC5A8SMCT1Inhibition4.20.2%Q8N695

Broader ChEMBL bioactivity targets: 30 (assay-derived). Sample: Dehydrogenase/reductase SDR family member 9, Prelamin-A/C, Solute carrier family 22 member 6, Solute carrier family 22 member 6, Retinoic acid receptor beta, Estrogen receptor, Cyclooxygenase, Prostaglandin G/H synthase (cyclooxygenase), Polyunsaturated fatty acid 5-lipoxygenase, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 95 potent at pChembl ≥ 5 of 127 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
LMNA8.25Potency5.6nMCHEMBL_ACT_3655867
PTGS27IC50100nMCHEMBL_ACT_917301
PTGS16.67IC50212nMCHEMBL_ACT_7662381
P224376.66IC50220nMCHEMBL_ACT_242732
NFKB16.65Potency223.9nMCHEMBL_ACT_3671929
NFKB16.65Potency223.9nMCHEMBL_ACT_4585211
PTGS16.54IC50290nMCHEMBL_ACT_13304008
P353556.22IC50600nMCHEMBL_ACT_18521077
Q057696.07IC50860nMCHEMBL_ACT_14569697
PTGS25.97IC501080nMCHEMBL_ACT_18493976
P059795.97IC501060nMCHEMBL_ACT_490365
PTGS25.96IC501100nMCHEMBL_ACT_12635494
P792085.96IC501100nMCHEMBL_ACT_1511306
PTGS25.96IC501100nMCHEMBL_ACT_16410618
PTGS25.96IC501100nMCHEMBL_ACT_16415047
P792085.96IC501100nMCHEMBL_ACT_1885023
Q80UJ15.96Ki1100nMCHEMBL_ACT_2202425
P792085.96IC501100nMCHEMBL_ACT_2380527
P792085.96IC501100nMCHEMBL_ACT_2501470
O626985.96IC501100nMCHEMBL_ACT_2613226
P792085.96IC501100nMCHEMBL_ACT_2641859
PTGS25.96IC501100nMCHEMBL_ACT_2986825
PTGS25.96IC501100nMCHEMBL_ACT_2997813
PTGS25.96IC501100nMCHEMBL_ACT_3093063
P792085.96IC501100nMCHEMBL_ACT_3095167
PTGS25.96IC501100nMCHEMBL_ACT_3258177
PTGS25.96IC501100nMCHEMBL_ACT_3372844
PTGS25.96IC501100nMCHEMBL_ACT_6254919
P792085.96IC501100nMCHEMBL_ACT_6379901
PTGS25.96IC501100nMCHEMBL_ACT_8056068

Target pathways

Aggregated over 6 target gene(s): SLC36A1, PTGS1, PTGS2, PPARG, ASIC1, SLC5A8.

Top Reactome pathways

31 total, by targets touching each:

PathwayTargetsGenes
Transport of small molecules3ASIC1, SLC36A1, SLC5A8
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
R-HSA-4253932SLC36A1, SLC5A8
SLC-mediated transmembrane transport2SLC36A1, SLC5A8
COX reactions1PTGS1
Metabolism1SLC5A8
Nicotinate metabolism1SLC5A8
Metabolism of water-soluble vitamins and cofactors1SLC5A8
Metabolism of vitamins and cofactors1SLC5A8
R-HSA-1972641SLC5A8
PPARA activates gene expression1PPARG
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Stimuli-sensing channels1ASIC1
Amino acid transport across the plasma membrane1SLC36A1
Transcriptional regulation of white adipocyte differentiation1PPARG
Nuclear Receptor transcription pathway1PPARG
SUMOylation of intracellular receptors1PPARG
Proton-coupled neutral amino acid transporters1SLC36A1
Organic anion transport by SLC5/17/25 transporters1SLC5A8
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Regulation of PTEN gene transcription1PPARG
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
MECP2 regulates transcription factors1PPARG
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2
Ion channel transport1ASIC1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis1PPARG
Transcriptional regulation of brown and beige adipocyte differentiation by EBF21PPARG

Dominant GO biological processes

GO termTargets
monoatomic ion transport3
regulation of blood pressure3
fatty acid metabolic process3
prostaglandin biosynthetic process2
response to oxidative stress2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
lipid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
brown fat cell differentiation2
cellular response to hypoxia2

Indications & clinical

Indications

86 indications (21 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
vaginitis4MONDO:0002234EFO:0005757
common cold4MONDO:0005709EFO:0007214
rheumatic disorder4MONDO:0005554EFO:0005755
cardiovascular disorder4MONDO:0004995EFO:0000319
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
rheumatoid arthritis4MONDO:0008383EFO:0000685
patent ductus arteriosus4MONDO:0011827HP:0001643
influenza4MONDO:0005812EFO:0007328
arthritic joint disease4MONDO:0005578EFO:0005856
pharyngitis4MONDO:0002258MONDO:0002258
osteoarthritis4MONDO:0005178MONDO:0005178
migraine disorder4MONDO:0005277MONDO:0005277
obstructive sleep apnea syndrome3MONDO:0007147EFO:0003918
bone fracture3MONDO:0005315EFO:0003931
peptic ulcer disease3MONDO:0004247HP:0004398
cerebral palsy3MONDO:0006497EFO:1000632
HIV infectious disease3MONDO:0005109EFO:0000764
breast neoplasm3MONDO:0021100EFO:0003869
altitude sickness3MONDO:0006625EFO:1000782
vasculitis3MONDO:0018882EFO:0006803
burn3MONDO:0043519EFO:0009516
toxic shock syndrome3MONDO:0001881EFO:0006834
acute respiratory distress syndrome3MONDO:0006502EFO:1000637
complex regional pain syndrome type 23MONDO:0020572EFO:1000854
pulpitis3MONDO:0006937EFO:1001139
hypospadias3MONDO:0005345EFO:0004209
tibia fracture3MONDO:0005320EFO:0003944
multiple sclerosis3MONDO:0005301MONDO:0005301
pulmonary emphysema2MONDO:0004849EFO:0000464
hypertensive disorder2MONDO:0005044EFO:0000537
spondyloarthropathy2MONDO:0005095EFO:0000706
retinopathy of prematurity2MONDO:0006952EFO:1001158
periodontitis2MONDO:0005076EFO:0000649
muscle tissue disorder2MONDO:0003939EFO:0002970
canker sore2MONDO:0005318EFO:0003938
sunburn2MONDO:0005326EFO:0003958
temporomandibular joint disorder2MONDO:0005473EFO:0005279
sinusitis2MONDO:0005961EFO:0007486
brachial plexus neuritis2MONDO:0006682EFO:1000843
tooth disorder2MONDO:0006999EFO:1001216
injury2MONDO:0021178EFO:0000546
preeclampsia2MONDO:0005081EFO:0000668
focal epilepsy2MONDO:0005384EFO:0004263
spondylosis, cervical2MONDO:0008481EFO:0009610
acute pancreatitis2MONDO:0006515EFO:1000652
major depressive disorder2MONDO:0002009MONDO:0002009
glioma2MONDO:0021042MONDO:0100342
enuresis2MONDO:0024290MONDO:0024290
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
tuberculosis2MONDO:0018076MONDO:0018076
chronic granulomatous disease2MONDO:0018305MONDO:0018305
bronchopulmonary dysplasia2MONDO:0019091MONDO:0019091
kidney cancer2MONDO:0002367MONDO:0002367
epilepsy2MONDO:0005027EFO:0000474
kidney neoplasm2MONDO:0021163EFO:0003865
osteoarthritis, knee1MONDO:0005416EFO:0004616
allergic rhinitis1MONDO:0011786EFO:0005854
orthostatic hypotension1MONDO:0005469EFO:0005252
malaria1MONDO:0005136EFO:0001068
Alzheimer disease1MONDO:0004975MONDO:0004975
Duchenne muscular dystrophy1MONDO:0010679MONDO:0010679
glycogen storage disease III1MONDO:0009291MONDO:0009291
acute kidney injury1MONDO:0002492HP:0001919
bipolar disorder1MONDO:0004985MONDO:0004985

22 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 578.

Phase distribution

PhaseTrials
PHASE4170
Not specified153
PHASE393
PHASE268
PHASE158
PHASE2/PHASE313
EARLY_PHASE112
PHASE1/PHASE211

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03060434PHASE4ACTIVE_NOT_RECRUITINGPentoxifylline and Lumbar Radiculopathy
NCT03759028PHASE4RECRUITINGSupracondylar Post-Operative Pain Study
NCT03858231PHASE4RECRUITINGOpioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
NCT04102566PHASE4RECRUITINGOptimizing Pain Control in Transurethral Resection of the Prostate
NCT05076110PHASE4RECRUITINGNonopioid Pain Control Regimen After Arthroscopic Hip Procedures
NCT05488847PHASE4ACTIVE_NOT_RECRUITINGOpioid-Free Pain Protocol After Shoulder Arthroplasty
NCT05512754PHASE4RECRUITINGImpact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
NCT05629494PHASE4RECRUITINGAnti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
NCT05721027PHASE4RECRUITINGIbuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.
NCT05919745PHASE4RECRUITINGPreemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft
NCT06398054PHASE4NOT_YET_RECRUITINGA Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy
NCT06434233PHASE4RECRUITINGOpioid Use After Laparoscopic Salpingectomy
NCT06479122PHASE4RECRUITINGEfficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section
NCT06495632PHASE4RECRUITINGScheduled or As Needed Pain Regimen?
NCT06505148PHASE4NOT_YET_RECRUITINGComparing the Difference in Pain Control in the Pediatric General Surgery Population: to Alternate or Combine Acetaminophen and Ibuprofen?
NCT06671002PHASE4RECRUITINGComparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
NCT06757075PHASE4RECRUITINGManagement of Postoperative Discomfort in Young Children Following Dental Rehabilitation Under General Anesthesia
NCT06786650PHASE4ACTIVE_NOT_RECRUITINGComparision of the Analgesic Effects of Intravenous Ibuprofen and Tenoxicam in Acute Migraine Attack
NCT07512297PHASE4NOT_YET_RECRUITINGPain Control During ESWL Using Non-Opioid Analgesics
NCT07571252PHASE4NOT_YET_RECRUITINGImpact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery
NCT07600697PHASE4NOT_YET_RECRUITINGSuzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery
NCT00046358PHASE4COMPLETEDThe Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer’s Disease
NCT00115336PHASE4TERMINATEDKetorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease
NCT00145730PHASE4COMPLETEDPrevention of Ectopic Bone Related Pain and Disability After Hip Replacement Surgery With Peri-Operative Ibuprofen
NCT00167713PHASE4COMPLETEDTreatment of Fever Due to Malaria With Ibuprofen
NCT00217191PHASE4COMPLETEDIbuprofen and Renal Function in Premature Infants
NCT00240825PHASE4COMPLETEDAn Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain.
NCT00240864PHASE4COMPLETEDAn Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain
NCT00261586PHASE4COMPLETEDA Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach
NCT00267293PHASE4COMPLETEDIbuprofen Alone and in Combination With Acetaminophen for Treatment of Fever
NCT00292747PHASE4TERMINATEDDrotaverine in Dysmenorrhoea Treatment
NCT00346216PHASE4COMPLETEDProspective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
NCT00382083PHASE4COMPLETEDPremedication to Reduce Discomfort With Screening Mammography
NCT00470743PHASE4WITHDRAWNComparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies
NCT00484744PHASE4COMPLETEDAcetaminophen Versus Ibuprofen for the Control of Immediate and Delayed Pain Following Orthodontic Separator Placement
NCT00565500PHASE4COMPLETEDCelecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin
NCT00568217PHASE4COMPLETEDAntipyretics for Preventing Recurrences of Febrile Seizures
NCT00620867PHASE4COMPLETEDEfficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)
NCT00630929PHASE4COMPLETEDEfficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)
NCT00631514PHASE4COMPLETEDInteraction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
PIK3CA AmplificationHead And Neck Squamous Cell CarcinomaSensitivity/ResponseIbuprofen + Aspirin + SulindacCIViC BEID7186

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (2) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

GuidelineSourceGene(s)DosingRecommendation
Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lCPICCYP2C9yesyes
Annotation of CPIC Guideline for diclofenac, ibuprofen and CYP2C8CPICCYP2C8

PharmGKB also curates 8 clinical and 50 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

478 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
KETOPROFENChEMBL + PubChemPhase 4 (approved)PTGS1, PTGS2, SLC5A8
INDOMETHACINChEMBLPhase 4 (approved)PPARG, PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PPARG, PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PPARG, PTGS1, PTGS2
RESVERATROLChEMBLPhase 3PPARG, PTGS1, PTGS2
CycloserineChEMBL + PubChemPhase 4 (approved)PTGS1, SLC36A1
cysteineChEMBL + PubChemPhase 4 (approved)PTGS1, SLC36A1
FENOPROFENChEMBL + PubChemPhase 4 (approved)PTGS1, SLC5A8
FulvestrantChEMBL + PubChemPhase 4 (approved)PPARG, PTGS2
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)PPARG, PTGS2
CANNABIDIOLChEMBLPhase 4 (approved)PPARG, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CELECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LASOFOXIFENEChEMBLPhase 4 (approved)PPARG, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVOTHYROXINEChEMBLPhase 4 (approved)PPARG, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
MASOPROCOLChEMBLPhase 4 (approved)PPARG, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MELOXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NAPROXENChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
OXAPROZINChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SULINDACChEMBLPhase 4 (approved)PPARG, PTGS2
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TIPRANAVIRChEMBLPhase 4 (approved)PPARG, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
VALDECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
CURCUMINChEMBLPhase 3PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot